Article

Sesquiterpenoids from *Inula britannica* and Their Potential Effects against Triple-Negative Breast Cancer Cells

Ruo-Yu Qi †, Cong Guo †, Xiao-Na Peng and Jiang-Jiang Tang *

Shaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry & Pharmacy, Northwest A&F University, Taicheng Road, Yangling 712100, China

* Correspondence: tangjiang11@nwafu.edu.cn; Tel.: +86-298-709-2335
† These authors contributed equally to this work.

Abstract: Flowers of *Inula britannica* commercially serve as pharmaceutical herbs in the manufacturing of medicinal products. In the current study, sesquiterpenoids of *I. britannica* flowers' extract and their potential effects against triple-negative breast cancer (TNBC) cells were investigated. Eight structurally diverse sesquiterpenoids, including one sesquiterpenoid dimer (1) and seven sesquiterpenoid monomers (2–8) were isolated from this source. The structures of all compounds were elucidated by 1D/2D NMR data, and their absolute configurations were discerned by single crystal X-ray diffraction. All of the compounds were tested for their potential effects against TNBC. Specifically, 5 displayed strong antiproliferative potency against TNBC cells with a high selective index (SI) on MCF-7 cells (SI > 4 of IC$_{50}$ on MDA-MB-468/IC$_{50}$ on MCF-7), and dimer 1 (IC$_{50}$ = 8.82 ± 0.85 µM) showed better antiproliferative potency against MCF-7 cells than the other monomers did (2–8) (IC$_{50}$ > 20 µM). To our best knowledge, compound 5 is the first sesquiterpenoid targeting TNBC cells.

Keywords: *Inula britannica*; sesquiterpenoid; triple-negative breast cancer; dimers

1. Introduction

The biggest cancer-related disease for women worldwide remains breast cancer (BrCa) [1,2]. BrCa subtypes are defined by their histopathological appearance and expression of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor 2 (HER2). Most of the cases are ER-positive and PR-positive BrCa, and hormone therapy normally shows really good effects in them [3]. HER2-positive BrCa takes about 15–20% of all kinds of BrCa. Today, numerous targeted anti-HER2 medications have been authorized for use in treating HER2-positive BrCa [4]. Unfortunately, 10–20% of BrCa is known as triple-negative breast cancer (TNBC) and shows a negative result for ER, PR and HER2 expression. TNBC, with poor overall survival (OS) and an aggressive clinical course, is a poorly understood BrCa type. The incidence of TNBC is amazingly high among overweight [5], non-Hispanic black, and younger women [3,5,6].

Because of the antioxidant and anti-neuroinflammatory activities they have, natural-product-derived bioactive agents have attracted attention on the development of preventive neuroprotectants or nutraceuticals for the treatment of neurodegenerative disorders [7–10]. In Eastern Asia, the *Inula britannica* plant has been used to treat disorders of the digestive system, bronchitis and inflammation for many years [11,12]. Numerous biologically active sesquiterpene lactones have been identified from this plant, according to earlier phytochemical studies [13]. Several studies have shown that certain sesquiterpene lactones can prevent breast cancer cells from migrating and invading [14,15]. For example, eupatolide lowers inflammation by inhibiting the nuclear factor-light-chain-enhancer of activated B cells, as well as preventing the production of tumor necrosis factor (TNF) and NO [16–18]. Moreover, it is also reported that eupatolide could play an essential role in the sensitization of TRAIL-induced apoptosis in human breast cancer cells. Therefore, it is
particularly important to explore novel bioactive metabolites from *I. britannica* flowers and their anti-tumor activities [13].

In our continuous efforts to explore natural products against TNBC, the *I. britannica* flowers was further investigated and isolated to obtain eight structurally diverse sesquiterpenoids, including one known sesquiterpenoid dimer (1) and seven known sesquiterpenoid monomers (2–8). The antiproliferative potential of the isolates was tested on breast cancer cell lines MDA-MB-231, MDA-MB-468 and MCF-7.

2. Results and Discussion

The dried flowers of *I. britanica* were pulverized and extracted with 95% aqueous ethanol, and the extract was successively partitioned with petroleum ether, CH$_2$Cl$_2$, and EtOAc. One known sesquiterpenoid dimer (1) and seven known sesquiterpenoid monomers (2–8) (Figure 1) were isolated from the column chromatography separation of the ethyl acetate layer. The eight compounds were identified as japonicone H (1) [19], 1β,4β-dihydroxy-8β-acetoxy-5αH-eudesma-11(13)-en-12-oic acid methyl ester (2) [20], 6β-hydroxytomentosin (3) [21], budlein B (4) [22,23], 1,10β-dihydroxy-4αH-1,10-secoeudesma-5(6),11(13)-dien-12,8β-olide (5) [18], 1β-hydroxy-11,13-dihydroisoantolactone (6) [24], 6-O-isobutyrylbritannilactone (7) [25,26], (1R,4S,5R,7R,8R,10S)-1,5-dihydroxy-eudesma-11(13)-en-12,8-olide (8) [20]. The structures of all isolates were well-characterized by 1D/2D NMR analysis referred to in the supplementary material.

![Chemical structure of sesquiterpenoids 1–8.](image)

Figure 1. Chemical structure of sesquiterpenoids 1–8.

Structurally, compound 1 is an endo [4+2] Diels–Alder dimeric sesquiterpene lactone of 1,10-secoeudesmanolides moiety and a guaiane monomer, which has been firstly isolated from *Inula japonica* Thunb [17]. In addition, compound 6 was also isolated from this species for the first time. The X-ray crystallographic analysis (Figure 2) showed that there was hydrogen bonding between the C$_8$-OH and C$_{15}$-OH in 4 that has not been reported in a previous study [23]. We also optimized the flack parameter from $-0.06$ (7) to $-0.04$ (5), which allowed us to get a more specific explicit assignment of the absolute structure.
Figure 2. X-ray crystal structure of 4 (Cu Kα radiation, flack parameter: 0.04 (5)). Grey balls are carbon (C), white balls are hydrogen (H), and red balls are oxygen (O).

The potent anticancer properties of sesquiterpenoids have been reported to be chemically mediated by the active motifs α-methylene-γ-butyrolactone that all these isolates contain. The α-methylene-γ-lactone group can form a covalent adduct with important cellular protein targets, such as -SH residues [27]. To examine whether isolates 1–8 have antiproliferative effects on breast cancer cells, triple-negative breast cancer cell lines MDA-MB-231 and MDA-MB-468, and estrogen receptor-positive breast cancer cell line MCF-7 were inoculated into 96-well plates. After incubating for 24 h, the medium was replaced with a fresh one containing the specified compounds (0.1, 0.5, 1, 5, 10, 20 μM). After 48 h, the antiproliferative effects were determined using the SRB assay by measuring cellular protein content. Doxorubicin (DOX) was used as the positive control. The IC₅₀ values are summarized in Table 1.

Table 1. Antiproliferative activities on breast cancer cells MDA-MB-231, MDA-MB-468 and MCF-7.

| Compound | IC₅₀ 1 (μM) |
|----------|-------------|
|          | MDA-MB-231 | MDA-MB-468 | MCF-7 |
| 1        | >20         | 6.68 ± 0.70 | 8.82 ± 0.85 |
| 2        | >20         | >20         | >20     |
| 3        | >20         | >20         | >20     |
| 4        | >20         | >20         | >20     |
| 5        | 11.5 ± 0.7  | 4.92 ± 0.65 | >20     |
| 6        | >20         | >20         | >20     |
| 7        | >20         | >20         | >20     |
| 8        | >20         | >20         | >20     |
| DOX 2    | 2.12 ± 0.19 | 0.53 ± 0.21 | 0.15 ± 0.21 |

1 IC₅₀ is the concentration that causes 50% inhibition of MDA-MB-231, MDA-MB-468 and MCF-7 breast cancer cells’ proliferation. The data were expressed as the means ± standard deviation. 2 Positive control: doxorubicin.

In the compound treatment periods, compound 1 showed antiproliferative activities against MDA-MB-468 and MCF-7 cells with IC₅₀ of 6.68 ± 0.70 μM and 8.82 ± 0.85 μM. However, with MDA-MB-231 cells, compound 1 did not show much of the antiproliferative activities with IC₅₀ > 20 μM. 1 as a sesquiterpenoid dimer showed better antiproliferative activities against MCF-7 breast cancer cells than all other seven sesquiterpenoid monomers. Compound 5 showed antiproliferative effects on MDA-MB-231 and MDA-MB-468 cells with IC₅₀ of 11.5 ± 0.71 μM and 4.92 ± 0.65 μM. However, 5 had no significant inhibitory effect on MCF-7 cells with IC₅₀ > 20 μM with a high selective index (SI > 4 of IC₅₀ on MDA-MB-468/IC₅₀ on MCF-7), implying that 5 displayed strong selective antiproliferative potency against TNBC cells. Other compounds (2–4, 6–8) retaining α-methylene moiety exhibited weak inhibitory effects against three BrCa cells. The result hinted the importance of the skeleton functionality of 5 but not only the α-methylene moiety in terms of anti-TNBC potency, which will be revealed in the future.
3. Materials and Methods

3.1. General

An Autopol III automatic polarimeter (Rudolph Research Analytical, NJ, USA) was used to measure the optical rotations. A Bruker Av-400 NMR spectrometer (Bruker BioSpin, Switzerland) was used to record the NMR spectra, with tetramethylsilane (TMS) as an internal standard at room temperature. Column chromatography (CC) was carried out using RP-18 gel (ODS-AQ-HGGEI, AQG12S50, YMC, Co., Ltd., Kyoto, Japan), silica gel (200–300 mesh, Qingdao Marine Chemical Industries, China) and Sephadex LH-20 (GE Healthcare, Uppsala, Sweden). Thin-layer chromatography (TLC) (Huanghui Marine Chemical, Ltd., Qingdao, China) was used to monitor the fractions. Agilent 1200 equipment with an Inert Sustain C18 column (5 µm particle size, 5 mm × 250 mm) was used to conduct HPLC analysis. Preparative HPLC was conducted on an NP7005C series instrument using a YMC-Pack ODS-A (10 × 250 mm).

3.2. Plant Materials

The I. britannica flowers were collected in October 2017 from the river-bed region of Qinling Moutain in Baoji City of Shaanxi province, China. Maintained dry and ventilated, the flowers were identified by Prof. Jun-Mian Tian. A voucher specimen (TJJ-201700119) was kept in a cool and dry environment of Shaanxi Key Laboratory of Natural Products & Chemical Biology, Northwest A&F University.

3.3. Extraction and Isolation

We used 95% EtOH (3 × 200 L) to extract the dried flowers of I. britannica. (50 kg) for 12 h at reflux. The combined extracts were then concentrated under reduced pressure to obtain the remaining extract (1.8 kg). After that, the mixture was dissolved in water (20 L) and partitioned with petroleum ether (3 × 20 L), CH₂Cl₂ (3 × 20 L) and ethyl acetate (3 × 20 L) in that order. To obtain fourteen fractions (F₁–F₁₄), the EtOAc-soluble fraction (360 g) was chromatographed on a silica gel column eluting with a CH₂Cl₂/MeOH (100:0–1:1 v/v) gradient. Fraction F₃ (64 g) was subjected to medium-pressure liquid chromatography (MPLC) over octadecylsilica (ODS) with a stepwise gradient of MeOH-H₂O (from 10% to 100%) to afford nine subfractions (F₃₁–F₃₉). Subfraction F₃₃ (5.6 g) was fractioned on silica gel CC with mixtures of CH₂Cl₂/MeOH (100:1-20:1 v/v) to afford twelve fractions (F₃₃₁–F₃₃₁₂). The further purification of F₃₃₁–F₃₃₁₂ by preparative HPLC (35% CH₃CN in water) afforded compound 3 (t_R = 25 min, 1.6 mg). Subfraction F₃₃₂ (5.6 g) was subjected to silica gel column chromatography (CC) with mixtures of DCM-MeOH (80:1-10:1 v/v) as eluents gradient to obtain ten fractions (F₃₂₁–F₃₂₁₀). Compound 2 (130.6 mg) was isolated after CC over Sephadex LH-20 from F₃₂. By the same procedures, compound 4 (6.7 mg) was obtained from F₃₂. Six fractions (F₃₅₁–F₃₅₆) were obtained by fractionating subfraction F₃₅ on silica gel CC using a gradient of PE-CH₃COCH₃ (8:1-1:1 v/v) mixtures as eluents. Compound 5 (t_R = 40 min, 3.6 mg) was obtained after further purification of F₃₅₂ using preparative HPLC (50% CH₃CN in water). Similarly, subfraction F₃₆ (3.9 g) was purified by a Sephadex LH-20 column (eluted with CH₂Cl₂/MeOH, v/v, 1:1) and then a silica gel column eluting with mixtures of PE-EtOAc (8:1-1:2 v/v) to yield four fractions (F₃₆₁–F₃₆₄). Compound 6 was then separated from F₃₆₁–F₃₆₄ by preparative TLC. Subfraction F₅ (3.2 g) was purified by a Sephadex LH-20 column (eluted with CH₂Cl₂/MeOH, v/v, 1:1) to yield four fractions (F₅₇₁–F₅₇₄), and compounds 7 (t_R = 25 min, 2.3 mg) and 8 (t_R = 37 min, 13.9 mg) were isolated from F₅₇₃ by preparative HPLC (50% CH₃CN in water). Fraction F₅ (64 g) was subjected to MPLC over ODS with a stepwise gradient of MeOH-H₂O (from 10% to 100%) to afford nine subfractions (F₅₁–F₅₉). Subfraction F₅₇ (2.0 g) was fractioned on silica gel CC with mixtures of PE-EtOAc (8:1-1:2 v/v) as eluents gradient to obtain twenty fractions (F₅₇₁–F₅₇₂₀). Compound 1 (1.3 mg) was isolated after CC over Sephadex LH-20 from F₅₇₁₄.
3.4. X-ray Crystallographic Analysis of 4

Crystal Data for C_{15}H_{20}O_{4} (M = 264.31 g/mol): orthorhombic, space group P2_1_2_1_2_1, a = 9.55914(9) Å, b = 10.00802(10) Å, c = 13.83442(15) Å, V = 1323.51(2) Å^3, Z = 4, T = 149.96(10) K, μ(Cu Kα) = 0.779 mm^{−1}, D_{calc} = 1.326 g/cm^3, 7356 reflections measured (10.912° ≤ 2θ ≤ 154.8°), 2626 unique (R_{int} = 0.0173, R_{sigma} = 0.0153), which were used in all calculations. The final R_1 was 0.0301 (I > 2σ(I)) and wR_2 was 0.1044 (all data).

3.5. Cell Culture

MDA-MB-231, MDA-MB-468 and MCF-7 breast cancer cells were seeded in T75 flasks at 2 × 10^6 cells/flask in high-glucose Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS), a 1% penicillin/streptomycin mix and were incubated at 37 °C in an atmosphere of 5% CO_2. The medium was renewed twice a week, and cells were passaged once a week at a subcultivation ratio of 1:3.

3.6. SRB Assay

This SRB method was based on SRB’s ability to stoichiometrically bind to proteins under mildly acidic conditions before being extracted under basic conditions. As a result, the amount of bound dye could approximately represent the cell mass, from which we could extrapolate to measure cell proliferation [28]. MDA-MB-231, MDA-MB-468 and MCF-7 breast cancer cells with the densities of 1.2 × 10^4, 8 × 10^3, and 8 × 10^3 (cells/well) were inoculated into 96-well plates for 24 h, then, the medium was replaced with a fresh one containing the specified compound. Eight compounds were configured into different media, and each compound was set with five different concentrations of 0.1, 0.5, 1, 5, 10, 20 µM. After 48 h of incubation, cell monolayers were fixed with 10% (w/v) trichloroacetic acid for 12 h, washed with distilled water six times, and stained by SRB (0.4%, w/v) for 30 min. Then, using 1% (v/v) acetic acid, the excess dye was removed from the cells by washing them repeatedly six times. The protein-bound dye was dissolved in 100 µL Tris base solution for optical density (OD) determination at 560 nm using a microplate reader.

3.7. Statistical Analysis

All tests were performed at least in triplicate. The data are displayed as the mean ± standard deviation (SD). The exhibited data were investigated by one-way analysis of variance (ANOVA) using Graph prism 8.0.

4. Conclusions

The phytochemical composition and antiproliferative effects of the sesquiterpenoid-enriched I. britannica flowers extract were reported. Eight sesquiterpenoid isolates (1–8), including one dimer and seven monomers, were isolated from I. britannica flowers. Importantly, all isolates were evaluated in vitro for their anti-TNBC properties. Specifically, 5 displayed strong antiproliferative potency against TNBC cells with high selective index (SI) on MCF-7 cells (SI > 4 of IC_{50} on MDA-MB-468/IC_{50} on MCF-7). Additionally, all of the monomers (2–8) (IC_{50} = 20 µM) showed weaker activities than that of the dimer (1) (IC_{50} = 8.82 ± 0.85 µM) on MCF-7 breast cancer cells. To our best knowledge, compound 5 is the first sesquiterpenoid targeting TNBC cells, which provides enlightenment for further research and development of these bioactive compounds as anti-TNBC agents.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules27165230/s1, Figures S1–S8: 1D, 2D NMR spectra of isolates 1–8; Table S1: Crystal data and structure refinement for 4.

Author Contributions: R.-Y.Q. and J.-J.T. conceived and designed the experiments; R.-Y.Q. and C.G. performed the experiments; C.G. and X.-N.P. analyzed the data; J.-J.T. contributed the reagents/materials and tools; R.-Y.Q. and J.-J.T. wrote the paper. All authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by the National Natural Science Foundation of China (No. 82073730).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Acknowledgments: The authors would like to thank Ping Xiang from the State Key Laboratory of Crop Stress Biology for Arid Areas, NWAFU, for analysis of HPLC-MS and NMR.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are available from the authors.

References

1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Jemal, A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries: Global Cancer Statistics 2018. CA Cancer J. Clin. 2018, 68, 394–424. [CrossRef] [PubMed]

2. Heer, E.; Harper, A.; Escandor, N.; Sung, H.; McCormack, V.; Fidler-Benoudia, M.M. Global burden and trends in premenopausal and postmenopausal breast cancer: A population-based study. Lancet Glob. Health 2020, 8, e1027–e1037. [CrossRef]

3. Friedman, S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 2000, 275, 2247–2250. [CrossRef]

4. Oh, D.Y.; Bang, Y.J. HER2-targeted therapies—A role beyond breast cancer. Nat. Rev. Clin. Oncol. 2020, 17, 33–48. [CrossRef] [PubMed]

5. Jiralerspong, S.; Goodwin, P.J. Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities. J. Clin. Oncol. 2016, 34, 4203–4216. [CrossRef]

6. Scott, L.C.; Mobley, L.R.; Kuo, T.; Il’Yasova, D. Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistic database, 2010 through 2014. Cancer 2019, 125, 3412–3417. [PubMed]

7. Currais, A.; Chiruta, C.; Goujon-Svrzic, M.; Costa, G.; Santos, T.; Batista, M.T.; Paiva, J.; do C<br>
8. Scott, L.C.; Mobley, L.R.; Kuo, T.; Il’Yasova, D. Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistic database, 2010 through 2014. Cancer 2019, 125, 3412–3417. [PubMed]

9. Kou, R.W.; Du, S.T.; Xia, B.; Zhang, Q.; Yin, X.; Gao, J.M. Phenolic and Steroidal Metabolites from the Cultivated Edible Inula japonica Thunb. with their inhibitory activities against LPS-induced NO production in RAW264.7 macrophages. J. Ethnopharmacol. 2016, 173, 1117–1120. [CrossRef] [PubMed]

10. Liu, F.; Dong, B.; Yang, X.; Yang, Y.; Zhang, J.; Jin, D.Q.; Ohizumi, Y.; Lee, D.; Xu, J.; Guo, Y. NO inhibitors function as potential anti-neuroinflammatory agents for AD from the flowers of Inula japonica. Bioorg. Chem. 2018, 77, 168–175. [CrossRef]

11. Khan, A.L.; Hussain, J.; Hamayun, M.; Gilani, S.A.; Ahmad, S.; Rehman, G.; Kim, Y.H.; Kang, S.M.; Lee, I.J. Secondary Metabolites in Urticaceae: A review of their biological activities and identification of neuroprotective compounds relevant to Alzheimer’s disease from medicinal plants of S. Tomé e Príncipe. J. Ethnopharmacol. 2014, 155, 830–840. [CrossRef]

12. Han, W.B.; Wang, G.Y.; Tang, J.J.; Wang, W.J.; Liu, H.; Gil, R.R.; Navarro-Vázquez, A.; Lei, X.; Gao, J.M. Herpotrichones A and B, Two Intermolecular [4 + 2] Adducts with Anti-Neuroinflammatory Activity from a Herpotrichia Species. Org. Lett. 2019, 22, 405–409. [CrossRef]

13. Lee, J.; Hwangbo, C.; Lee, J.I.; Seo, J.; Lee, J.H. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression. Oncol. Rep. 2009, 23, 229–237. [CrossRef]

14. Kobayashi, T.; Song, Q.H.; Hong, T.; Kitamura, H.; Cyong, J.C. Preventative effects of the flowers of Inula japonica on autoimmune diabetes in C57BL/KsJ mice induced by multiple low doses of streptozotocin. Phytochem. Res. 2002, 16, 377–382. [CrossRef] [PubMed]

15. Rafi, M.M.; Bai, N.S.; Chi-Tang-Ho; Rosen, R.T.; Dipaola, R.S. A sesquiterpenelactone from Inula britannica L. and Their Biological Activities. Molecules 2010, 15, 1562–1577. [CrossRef] [PubMed]

16. Lee, Y.H.; Lee, N.K.; Paik, H.D. Antimicrobial Characterization of Inula britannica against Helicobacter pylori on Gastric Condition. J. Microbiol. Biotech. 2016, 26, 1011–1017. [CrossRef] [PubMed]

17. Lee, J.; Hwangbo, C.; Lee, J.I.; Seo, J.; Lee, J.H. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression. Oncol. Rep. 2009, 23, 229–237. [CrossRef]

18. Kobayashi, T.; Song, Q.H.; Hong, T.; Kitamura, H.; Cyong, J.C. Preventative effects of the flowers of Inula japonica on autoimmune diabetes in C57BL/KsJ mice induced by multiple low doses of streptozotocin. Phytochem. Res. 2002, 16, 377–382. [CrossRef] [PubMed]

19. Rafi, M.M.; Bai, N.S.; Chi-Tang-Ho; Rosen, R.T.; Dipaola, R.S. A sesquiterpenelactone from Inula britannica L. and Their Biological Activities. Molecules 2010, 15, 1562–1577. [CrossRef] [PubMed]

20. Whitman, M.; Raftery, L. TGFβ signaling at the summit. Development 2005, 132, 4205–4210. [CrossRef]

21. Zhang, Y.E. Non-Smad pathways in TGF-β signaling. Cell Res. 2009, 19, 128–139. [CrossRef]

22. Boldbaatar, A.; Lee, S.; Han, S.; Jeong, A.L.; Ka, H.I.; Buyanravjikh, S.; Lee, J.H.; Lim, J.S.; Lee, M.S.; Yang, Y. Eupatolide inhibits the TGF-beta1-induced migration of breast cancer cells via downregulation of SMAD3 phosphorylation and transcriptional repression of ALK5. Oncol. Lett. 2017, 14, 6031–6039.

23. Qin, J.J.; Jin, H.Z.; Zhu, J.X.; Fu, J.J.; Hu, X.J.; Liu, X.H.; Zhu, Y.; Yan, S.K.; Zhang, W.D. Japonicenes E-L, dimeric sesquiterpene lactones from Inula japonica Thunb. Planta Med. 2010, 76, 278–283. [CrossRef]

24. Qin, J.J.; Jin, H.-Z.; Zhu, J.-X.; Fu, J.-J.; Zeng, Q.; Cheng, X.-R.; Zhu, Y.; Shan, L.; Zhang, S.-D.; Pan, Y.-X.; et al. New sesquiterpenes from Inula japonica Thunb. with their inhibitory activities against LPS-induced NO production in RAW264.7 macrophages. Tetrahedron 2010, 66, 9379–9388. [CrossRef]

25. Nie, L.Y.; Qin, J.J.; Huang, Y.; Yan, L.; Liu, Y.B.; Pan, Y.X.; Jin, H.Z.; Zhang, W.D. Sesquiterpenoids from Inula lineariifolia inhibit Nitric Oxide Production. J. Nat. Prod 2010, 73, 1117–1120. [CrossRef] [PubMed]
22. Zhou, B.N.; Bai, N.S.; Lin, L.Z.; Cordell, G.A. Sesquiterpene lactones from Znula Salsolozdes. *Phytochemistry* 1993, 36, 721–724. [CrossRef]

23. Wu, X.D.; Ding, L.F.; Tu, W.C.; Yang, H.; Su, J.; Peng, L.Y.; Li, Y.; Zhao, Q.S. Bioactive sesquiterpenoids from the flowers of *Inula japonica*. *Phytochemistry* 2016, 129, 68–76. [CrossRef] [PubMed]

24. Xie, W.D.; Wang, X.R.; Ma, L.S.; Li, X.; Row, K.H. Sesquiterpenoids from *Carpesium divaricatum* and their cytotoxic activity. *Fitoterapia* 2012, 83, 1351–1355. [CrossRef] [PubMed]

25. Jang, D.K.; Pham, C.H.; Lee, I.S.; Jung, S.H.; Jeong, J.H.; Shin, H.S.; Yoo, H.M. Anti-Melanogenesis Activity of 6-O-Isobutyrylbrittanilactone from *Inula britannica* on B16F10 Melanocytes and In Vivo Zebrafish Models. *Molecules* 2020, 25, 3887–3900. [CrossRef] [PubMed]

26. Jakupovic, J.; Lehmann, L.; Bohlmann, F.; King, R.M.; Robinson, H. Sesquiterpene lactones and other constituents from *Cassinia, Actinobole* and *Anaxeton* species. *Phytochemistry* 1988, 27, 3831–3839. [CrossRef]

27. Janecka, A.; Wyrebska, A.; Gach, K.; Fichna, J.; Janecki, T. Natural and synthetic alpha-methylenelactones and alphamethyleneacetams with anticancer potential. *Drug Discov. Today* 2012, 17, 561–572. [CrossRef]

28. Li, Q.; Wang, Z.; Xie, Y.; Hu, H. Antitumor activity and mechanism of costunolide and dehydrocostus lactone: Two natural sesquiterpene lactones from the Asteraceae family. *Biomed. Pharmacother* 2013, 125, 109955. [CrossRef]